Fundraising FoxAnzu Partners — 2020 Investments
5 investments dated 2020 · listed companies and verified rows first · show all
Bioskryb provides genomic sequencing and single-cell analysis solutions for biopharmaceutical companies and clinical researchers, enabling them to characterize circulating tumor cells, identify biomarkers, and support drug development across oncology, neurology, and cell/gene editing applications.
AI & Machine LearningBiotechDigital HealthMedical Devices
Chuck Gawad(Chief Scientific Officer / Co-Founder)
Co-investorsSeed Healthcare
CAR-Macrophage cellular therapeutics with initial oncology focus (NASDAQ: CARM).
BiotechPhiladelphia, US
Steven Kelly(Executive Officer, Director)in
BoardMargarita Chavez(Director)inEran Nadav(Director)Althea Stillman(Director)Jacob Gunterberg(Director)Regina Hodits(Director)in
Co-investorsAgent CapitalAju IB InvestmentGrazia Equity GmbHHealthCapMRL Ventures FundSolasta Ventures+3 more
ImmunoScape is a Singapore-based biotechnology company developing high-throughput immune profiling and therapeutic T cell receptor discovery platforms for immunotherapy and cancer treatment.
BiotechDeep TechHealthtechMedical DevicesSingapore, SG
Michael Fehlings, PhD(Co-founder, Chief Executive Officer)Evan Newell, PhD(Co-founder/Advisor)Alessandra Nardin, DVM(Co-founder, Vice President Strategy)
InterVenn applies glycoproteomics combined with artificial intelligence to study women's health conditions such as ovarian cancer and endometriosis, mapping glycoprotein control points linked to disease progression.
AI & Machine LearningBiotechFemTech
Aldo Carrascoso(Founder)Carlito Lebrilla(Founder)inCarolyn Bertozzi(Founder)
Co-investorsAmplify PartnersGenoa VenturesSoftBank Vision FundXeraya CapitalTrue Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.